New schizophrenia pill enters human safety testing

NCT ID NCT07230652

Recruiting now Disease control Sponsor: Luye Pharma Group Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests the safety and tolerability of a new extended-release tablet called LY03020 in 40 Chinese adults, including healthy volunteers and people with stable schizophrenia. The drug is also being explored for psychosis related to Alzheimer's disease. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. This is an early-stage study, so it focuses on safety rather than effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY03020 (extended-release tablet)
What this could lead to: If successful, this could lead to a new oral medication option for managing schizophrenia and Alzheimer's-related psychosis.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, focused on safety and dosing. It is not designed to prove the drug works, and many early-stage drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE PSYCHOSIS SCHIZOPHRENIA

Contacts and locations

Locations

Beijing AnDing Hospital Capital Medical University
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.